MOTS-c vs SS-31 (Elamipretide)
Mitochondrial-Derived Peptide · Mitochondrial-Targeted Peptide
Here is how these two compounds compare, based on published research, not marketing claims.
MOTS-c
An endogenous mitochondrial-derived peptide that activates AMPK for metabolic flexibility; levels decline with age.
SS-31
A synthetic peptide that stabilizes the inner mitochondrial membrane by binding cardiolipin; the most advanced mitochondrial-targeted peptide in clinical development.
MOTS-c
194 studies
19 human trials
Not FDA-Approved
SS-31
481 studies
23 human trials
Not FDA-Approved
What it does
MOTS-c
Activates AMPK, the master metabolic switch, to improve how cells use energy. Functions as an exercise mimetic in animal models, improving glucose uptake and fatty acid oxidation in skeletal muscle. Encoded within mitochondrial DNA and produced naturally by the body, with levels declining with age.
SS-31
Stabilizes the inner mitochondrial membrane by binding cardiolipin, reducing oxidative damage to the cellular energy production machinery. The most advanced synthetic mitochondrial-targeted peptide in clinical development, with multiple Phase II and Phase III trials for mitochondrial diseases.
How it works
MOTS-c
MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial genome (specifically within the 12S rRNA gene), making it one of the first identified mitochondrial-derived peptides. It activates AMP-activated protein kinase (AMPK), the central energy sensor that cells use to respond to low energy states. AMPK activation drives glucose uptake into skeletal muscle, increases fatty acid oxidation, and promotes mitochondrial biogenesis. In animal models, MOTS-c administration mimics some of the metabolic benefits of exercise, improving insulin sensitivity and metabolic flexibility.
SS-31
SS-31 (elamipretide) is a synthetic tetrapeptide that concentrates on the inner mitochondrial membrane where it binds cardiolipin, a specialized lipid essential for the electron transport chain. The electron transport chain is where cells produce ATP (their primary energy currency). By stabilizing cardiolipin, SS-31 preserves the structural integrity of the energy production machinery and reduces the reactive oxygen species (ROS) that damage mitochondria from within. The mechanism is structural reinforcement rather than signaling: SS-31 protects the physical components of energy production.
How often
MOTS-c
In published research, MOTS-c has been administered as subcutaneous injection in animal models and a small number of human studies. No FDA-approved product exists. No standardized dosing protocol has been established through regulatory channels.
SS-31
In clinical trials, SS-31 (elamipretide) has been administered as subcutaneous injection. Multiple Phase II and Phase III trials have been conducted for primary mitochondrial myopathy, Barth syndrome, and other mitochondrial conditions. Not yet FDA-approved despite reaching Phase III.
How strong
MOTS-c
The AMPK-activation mechanism is well-characterized at the cellular level. Animal models show consistent metabolic improvements: enhanced glucose uptake, improved insulin sensitivity, and exercise capacity effects. The endogenous origin (mitochondrial DNA-encoded) provides biological plausibility. Five published human studies document metabolic effects. The age-related decline of endogenous MOTS-c levels is documented, providing the theoretical basis for supplementation research.
SS-31
The most clinically advanced mitochondrial-targeted peptide. Phase II and Phase III trials across multiple mitochondrial diseases. The cardiolipin-binding mechanism is well-characterized. Published human safety and preliminary efficacy data from multiple trials. Represents a genuinely novel approach to mitochondrial medicine (structural membrane protection rather than metabolic signaling).
Main tradeoff
MOTS-c
Human data is limited to a small number of studies. The exercise-mimetic effects observed in animal models have not been fully replicated in human controlled trials at therapeutic scale. Whether exogenous MOTS-c supplementation can meaningfully rescue the age-related decline in endogenous levels is an open question. Not FDA-approved. The mitochondrial-derived peptide field is relatively new and the long-term effects of supplementation are not characterized.
SS-31
Despite reaching Phase III trials, some studies have not met primary endpoints. The FDA approval pathway has been challenging. Mitochondrial diseases are heterogeneous, and response variability across patient populations has complicated trial design. Not yet FDA-approved for any indication despite years of clinical development. The compound is specific to mitochondrial membrane protection and does not address all mechanisms of mitochondrial dysfunction.
Best for
MOTS-c
- Research on AMPK-mediated metabolic regulation and exercise mimetics
- Research on mitochondrial-derived peptides and their role in aging and metabolic health
- Research comparing mitochondrial-targeted interventions (MOTS-c, SS-31, humanin) across different mechanisms
SS-31
- Research on cardiolipin-mediated mitochondrial membrane stabilization
- Research on mitochondrial disease therapeutics with advanced clinical trial data
- Research comparing structural mitochondrial protection (SS-31) versus metabolic mitochondrial activation (MOTS-c)
How to choose
A good fit for MOTS-c
- Research on endogenous mitochondrial-derived peptides and age-related decline
- Research on AMPK-mediated metabolic regulation and exercise mimetics
- Research on the supplementation hypothesis for declining endogenous peptides
A good fit for SS-31
- Research on mitochondrial membrane stabilization and cardiolipin biology
- Research contexts where Phase II/III clinical trial data carries weight
- Research on specific mitochondrial diseases (Barth syndrome, primary myopathy)
Consider both across time
MOTS-c and SS-31 represent complementary approaches to mitochondrial health. MOTS-c addresses the metabolic signaling side (activating AMPK to improve how cells use energy). SS-31 addresses the structural side (stabilizing the membrane where energy production happens). They target different bottlenecks and are not competitive. For age-related mitochondrial decline, MOTS-c addresses the declining endogenous signal; SS-31 addresses the structural damage that accumulates. Neither is FDA-approved.
Dosing should be determined by a qualified physician who can evaluate individual circumstances. PSI does not provide personalized dosing guidance.
Official dosing references
- DailyMed(NIH drug labels)
- ClinicalTrials.gov
- PubMed
For readers who want the biology: here is the pathway each compound uses to signal the body. This section is optional. The comparison above covers the practical differences.
▶See the biology
- AMPK Activation
- AMPK Activation increases Glucose Uptake
- AMPK Activation drives Fatty Acid Oxidation
- AMPK Activation promotes Mitochondrial Biogenesis
- Glucose Uptake connects to Metabolic Flexibility; Fatty Acid Oxidation connects to Metabolic Flexibility
- Mitochondrial Biogenesis connects to Exercise Capacity
- Cardiolipin Binding
- Cardiolipin Binding stabilizes Inner Mitochondrial Membrane Stabilization
- Inner Mitochondrial Membrane Stabilization reduces ROS Reduction
- Inner Mitochondrial Membrane Stabilization supports ATP Production Support
- ROS Reduction connects to Mitochondrial Function Preservation
- ATP Production Support connects to Cellular Energy Maintenance
MOTS-c activates AMPK, the master metabolic switch, to improve glucose uptake, fatty acid oxidation, and mitochondrial biogenesis.
SS-31 binds cardiolipin in the inner mitochondrial membrane, stabilizing the energy production machinery and reducing oxidative damage.
Research Evidence
SS-31 has more advanced clinical development: multiple Phase II and Phase III trials for specific mitochondrial diseases, with published human safety and efficacy data. Some trials did not meet primary endpoints, complicating the regulatory path. MOTS-c has earlier-stage human data (five published studies documenting metabolic effects) with no formal clinical trial program. Both compounds have extensive mechanistic and animal model data.
- 1.
For specific mitochondrial diseases, SS-31 has more targeted clinical data.
- 2.
For metabolic optimization and exercise mimetic effects, MOTS-c has more relevant research.
- 3.
For age-related mitochondrial decline, both have mechanistic rationale but neither has definitive outcome data.
- 4.
For clinical development maturity, SS-31 is further along with more advanced trials.
Key Limitations
- •No head-to-head comparison.
- •Neither is FDA-approved.
- •SS-31 trials target specific diseases, results may not generalize.
- •MOTS-c human data is early-stage.
- •Both are at the frontier of mitochondrial medicine.
Community Discussion
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
MOTS-c
"MOTS-c is the longevity peptide everyone should be taking"
Plausible but unproven
"It improves exercise performance and endurance"
Supported by published data
"People are using it as a metabolic reset"
Anecdotal only
SS-31 (Elamipretide)
"SS-31 is the most advanced mitochondrial peptide"
Supported by evidence
"SS-31 reverses mitochondrial aging"
Plausible but unproven in humans
Safety Comparison
SS-31 has more formal safety data from clinical trials: injection site reactions and mild systemic effects reported. MOTS-c is an endogenous peptide the body naturally produces, providing biological plausibility for safety, but exogenous supplementation safety has not been formally characterized in controlled trials. Neither is FDA-approved.
MOTS-c
Limited but favorable. Endogenous peptide. No serious adverse events in published human studies.
SS-31 (Elamipretide)
Clinical trial safety data available. Side effects include injection site reactions. Generally well-tolerated in trials.
What the Research Suggests
SS-31 is further in clinical development with more advanced trials. MOTS-c has broader metabolic research and the unique advantage of being an endogenous signaling molecule. Both represent the cutting edge of mitochondrial medicine.